Actively Recruiting
Exploring the Possible Beneficial Impact of Non-invasive and Invasive Neuromodulation on Freezing of Gait in Parkinson's Disease During Different Ambulatory Complexities: An Electrophysiological and fMRI Study
Led by China Medical University Hospital · Updated on 2024-08-21
20
Participants Needed
1
Research Sites
169 weeks
Total Duration
On this page
Sponsors
C
China Medical University Hospital
Lead Sponsor
M
Ministry of Science and Technology, Taiwan
Collaborating Sponsor
AI-Summary
What this Trial Is About
Freezing of gait (FOG) stands out as a devastating symptom of Parkinson's disease (PD), where patients may become momentarily glued to the ground, rendering them incapable of walking efficiently. The pathogenesis of FOG remains uncertain but is likely attributed to functional perturbations in superficial cortical and deep locomotion regions. FOG tends to manifest more prominently during complex walking, such as turning, than during simple straight forward walking, and the reasons for this phenomenon remain unclear. Unfortunately, effective methods for overcoming this ambulatory issue has yet to be identified, and quantifying paroxysmal gait spells proves challenging with clinical rating alone; thus, a scientific tool is warranted. In this 3-year proposal, the investigators plan to address these challenges comprehensively.
CONDITIONS
Official Title
Exploring the Possible Beneficial Impact of Non-invasive and Invasive Neuromodulation on Freezing of Gait in Parkinson's Disease During Different Ambulatory Complexities: An Electrophysiological and fMRI Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients meet the diagnosis of Parkinson's disease based on established consensus criteria
- Age above 20 years old and below 90 years
- For MRgFUS patients: at least one cardinal symptom (akinesia, tremor, rigidity) with intensity of at least 2/4
- Parkinsonian symptoms not satisfactorily controlled by optimal medication including L-dopa
- Stable Parkinson's medication for at least 30 days
- DBS patients must have Parkinson's disease for more than 5 years
- DBS patients must show at least 33% improvement in UPDRS motor score after levodopa
- DBS patients must have motor complications such as wearing off, on-off episodes, levodopa-related dyskinesia, or intractable tremor
You will not qualify if you...
- Congestive heart failure Functional Class III or above
- Advanced cancer with distant metastasis
- Parkinson's disease at Hoehn and Yahr Stage 5
- For DBS patients: overt dementia or major depression
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
China Medical University Hospital/Neuro Depart
Taichung, Taiwan, 40447
Actively Recruiting
Research Team
C
Chon-Haw Tsai, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here